Target intelligence / Profile preview

Vipera ammodytes venom phospholipase A2 toxins (Vaa-PLA2)

Target
Vaa-PLA2
Molecular classification
Enzyme, Secreted phospholipase A2, Group IIA phospholipase A2
01

Overview

Vipera ammodytes venom phospholipase A2 (PLA2) toxins are a family of secreted enzymes and their non-enzymatic homologs found in the venom of the nose-horned viper, which is considered the most dangerous venomous snake in Europe (Wikipedia, 2024). The most prominent members are the ammodytoxins (AtxA, AtxB, and AtxC), which act as potent presynaptic beta-neurotoxins by inhibiting the release of neurotransmitters at the neuromuscular junction, leading to flaccid paralysis (NIH, 1994; Toxins, 2022). These toxins also exhibit myotoxic, anticoagulant, and pro-inflammatory activities, contributing to local tissue damage and systemic envenomation symptoms (NIH, 2011; NIH, 2017). In the context of drug development, these toxins are primary targets for neutralization by antivenoms and small-molecule inhibitors like varespladib (MDPI, 2024; Toxins, 2016). Varespladib acts as a competitive inhibitor of the PLA2 enzymatic site, effectively blocking the cascade of events that leads to neurotoxicity and tissue necrosis (Encyclopedia MDPI, 2024). Antivenoms, such as Viperatab, work by binding to and neutralizing the toxins before they can reach their physiological targets (MDPI, 2024).

Other names
AmmodytoxinsAtxNose-horned viper phospholipase A2Beta-neurotoxinsVipera ammodytes sPLA2
02

Mechanism of action

Competitive inhibition of phospholipase A2 enzymatic activity and neutralization by specific antibodies.

03

Biological functions

Phospholipid hydrolysisNeurotransmission inhibitionMyotoxicityAnticoagulant activityPro-inflammatory activity
04

Disease associations

Snakebite envenomationNeurotoxicityMyonecrosisInflammation
05

Safety considerations

Anaphylaxis to antivenomSerum sicknessRapid onset of respiratory paralysis
06

Interacting drugs

Varespladib

2 more in the full profile.

07

Biomarkers

Creatine kinasePhospholipase A2 activityProthrombin time

Beyond the preview

Go deeper on Vipera ammodytes venom phospholipase A2 toxins (Vaa-PLA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vipera ammodytes venom phospholipase A2 toxins (Vaa-PLA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call